Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by ALLEN, J. M.
Right arrow Articles by BLOOM, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ALLEN, J. M.
Right arrow Articles by BLOOM, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 109, No. 1, 143-157, 1986
© 1986 Oxford University Press

research-article

NEUROPEPTIDES AND DOPAMINE IN THE MARMOSET

EFFECT OF TREATMENT WITH 1-METHYL-4-PHENYL-1, 2, 3, 6 TETRAHYDROPYRIDINE (MPTP): AN ANIMAL MODEL FOR PARKINSON'S DISEASE?

J. M. ALLEN1,2, A. J. CROSS2, J. C. YEATS1, M. A. GHATEI1, G. P. MCGREGOR1, S. P. CLOSE3, S. PAY3, A. S. MARRIOTT3, M. B. TYERS3, T. J. CROW2 and S. R. BLOOM1,

1Department of Medicine, Royal Postgraduate Medical School Londoon 2Division of Psychiatry, Clinical Research Centre, Northwick Park Hospital Harrow, Middlesex 3Department of Neuropharmacology, Glaxo Group Research Ltd Ware, Hertfordshire

Correspondence to: Correspondence to: Professor S. R. Bloom, Royal Postgraduate Medical School, Du Cane Road, London, W12 0HS.

Neurochemical studies of post-mortem human parkinsonian brains have demonstrated specific alterations in neuropeptide concentrations within the substantia nigra and striatal structures The drug, 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropydine (MPTP) has been reported to act as a selective toxin to nigrostriatal dopamine neurons, and induces a parkinsonian-like syndrome in primates In this study, marmosets developed features typical of Parkinson' disease following treatment with MPTP for four days. The effects of MPTP treatment on the concentrations of dopamine and neuropeptides were determined and changes compared with those reported for Parkinson' disease It was found that within the substantia nigra, substance P concentrations doubled following treatment with MPTP, in contrast, concentrations of vasoactive intestinal peptide and neuropeptide Y were significantly reduced. No changes were observed in the concentrations of six other neuropeptides measured in this region, notably cholecystokinin. Despite marked depletion of dopamine within the caudate nucleus and putamen, concentrations of all neuropeptides within these structures remained unchanged with the exception of an isolated reduction of neuropeptide Y within the putamen. Somatostatin concentrations within the frontal cortex and hippocampus were significantly elevated in the marmosets treated with MPTP. These neuropeptide changes in the CNS contrast with those reported for Parkinson' disease In view of the autonomic dysfunction associated with Parkinson' disease, peripheral concentrations of neuropeptides were determined. Significant depletion of neuropeptide Y was identified in the ureter, adrenal and cardiovascular tissue. Thus the neurochemical changes induced by MPTP may not be as selective as previously reported.

Received January 30, 1985. Revised May 3, 1985. Accepted May 21, 1985.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
A.J. Stoessl
Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders
J Psychopharmacol, January 1, 1989; 3(2): 99 - 120.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.